Urban Oliver Y, Driedger Jan H, Garbade Sven F, Hoffmann Georg F, Kölker Stefan, Ries Markus, Syrbe Steffen
Division of Pediatric Epileptology, Center for Pediatric and Adolescent Medicine, Clinic 1, Medical Faculty of Heidelberg, Heidelberg University, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, Clinic 1, Medical Faculty of Heidelberg, Heidelberg University, Heidelberg, Germany.
Orphanet J Rare Dis. 2024 Dec 4;19(1):457. doi: 10.1186/s13023-024-03375-8.
Aicardi syndrome is a rare epileptic encephalopathy, almost exclusively affecting girls. It was first described as a triad of infantile spasms, chorioretinal defects and agenesis of the corpus callosum. The etiology remains unknown and there is uncertainty on best practice therapy and outcome. We aimed at defining quantitative clinical endpoints that will inform future research and clinical trials.
Quantitative natural history modeling of cases with Aicardi syndrome from published clinical reports. Main outcome measures were age at disease onset, survival and diagnostic delay. Phenotypic features of affected individuals as well as neuroradiological and ophthalmological features were descriptively stated. STROBE criteria were respected.
Two hundred forty-five cases were available for analysis. Median age at disease onset was 2.2 months. Median diagnostic delay was 1 month. Mortality was estimated with 6% at 1 and 17% at 5 years of age. 60% of children showed the classic clinical features, while 40% met the revised diagnostic criteria. We delineate possible predictors of disease severity and of seizure control.
We provide natural history data including geographical localization of 245 published patients with Aicardi syndrome. Quantitative history modeling in rare epileptic encephalopathies will help to raise disease awareness and facilitate future clinical trials as one core element of quantitative systems pharmacology.
艾卡迪综合征是一种罕见的癫痫性脑病,几乎仅影响女孩。它最初被描述为婴儿痉挛、脉络膜视网膜缺损和胼胝体发育不全三联征。病因尚不清楚,最佳治疗方法和预后也存在不确定性。我们旨在确定定量临床终点,为未来的研究和临床试验提供参考。
对已发表临床报告中的艾卡迪综合征病例进行定量自然史建模。主要结局指标为发病年龄、生存率和诊断延迟。对受影响个体的表型特征以及神经放射学和眼科特征进行了描述性说明。遵循了加强流行病学观察性研究报告标准(STROBE)。
245例病例可供分析。发病年龄中位数为2.2个月。诊断延迟中位数为1个月。估计1岁时死亡率为6%,5岁时为17%。60%的儿童表现出典型临床特征,40%符合修订后的诊断标准。我们描述了疾病严重程度和癫痫控制的可能预测因素。
我们提供了245例已发表的艾卡迪综合征患者的自然史数据,包括地理分布。罕见癫痫性脑病的定量病史建模将有助于提高对该疾病的认识,并促进未来的临床试验,这是定量系统药理学的一个核心要素。